Agenus (Agenus) Accounts Payable & Accrued Expense : $101.5 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Agenus Accounts Payable & Accrued Expense?

Agenus's quarterly accounts payable & accrued expense declined from Jun. 2023 ($77.6 Mil) to Sep. 2023 ($73.2 Mil) but then increased from Sep. 2023 ($73.2 Mil) to Dec. 2023 ($101.5 Mil).

Agenus's annual accounts payable & accrued expense increased from Dec. 2021 ($65.5 Mil) to Dec. 2022 ($72.7 Mil) and increased from Dec. 2022 ($72.7 Mil) to Dec. 2023 ($101.5 Mil).

Agenus Accounts Payable & Accrued Expense Historical Data

The historical data trend for Agenus's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agenus Accounts Payable & Accrued Expense Chart

Agenus Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

42.90

40.04

65.50

72.68

101.48

Agenus Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															72.68	75.19	77.57	73.18	101.48

Agenus Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Agenus (Agenus) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agenus Inc (NAS:AGEN) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

AJ81:Germany AJ81:Germany

Address

3 Forbes Road, Lexington, MA, USA, 02421

Website

https://www.agenusbio.com

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Executives

Ulf Wiinberg	director
Steven J O'day	officer: Chief Medical Officer	2344 BANYAN DRIVE, LOS ANGELES CA 90049
Garo H Armen	officer: Chairman & CEO	3 FORBES ROAD, LEXINGTON MA 02421
Christine M Klaskin	officer: VP Finance	3 FORBES ROAD, LEXINGTON MA 02421
Adam Krauss	officer: Chief Legal Officer	139 GRANIT STREET, MEDFIELD MA 02052
Susan B Hirsch	director	280 OLD SOMERSET ROAD, WATCHUNG NJ 07069
Paul N Clark	director	5301 STEVENS CREEK BLVD, MS 1A-LC, SANTA CLARA CA 95051
Incyte Corp	10 percent owner	1801 AUGUSTINE CUT-OFF, WILMINGTON DE 19803
Alex Duncan	officer: Chief Technology Officer	3 FORBES ROAC, LEXINGTON MA 02421
Christian Cortis	officer: See Remarks	3 FORBES ROAD, LEXINGTON MA 02421
Evan Kearns	officer: V.P. and General Counsel	AGENUS INC., 3 FORBES ROAK, LEXINGTON MA 02421
Jennifer Buell	officer: Chief Operating Officer	3 FORBES ROAD, LEXINGTON MA 02421
Allison M Jeynes-ellis	director	FLAT 52, WILLIAM HUNT MANSIONS, LONDON X0 SW13 8HT
Wadih Jordan	director	ANTIGENICS INC., 162 FIFTH AVE., SUITE 900, NEW YORK NY 10010
Brian Corvese	director	C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010